Deer Management Company’s TScan Therapeutics TCRX Stock Holding History

Deer Management Company’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.22M	Hold	1,245,504	–	–	0.15%	9
2026 Q1	$1.26M	Hold	1,245,504	–	–	0.2%	9
2025 Q4	$1.25M	Hold	1,245,504	–	–	0.12%	8
2025 Q3	$2.27M	Hold	1,245,504	–	–	0.2%	9
2025 Q2	$1.81M	Hold	1,245,504	–	–	0.14%	9
2025 Q1	$1.72M	Hold	1,245,504	–	–	0.16%	9
2024 Q4	$3.79M	Hold	1,245,504	–	–	0.3%	10
2024 Q3	$6.2M	Hold	1,245,504	–	–	0.98%	10
2024 Q2	$7.29M	Hold	1,245,504	–	–	1.5%	10
2024 Q1	$9.89M	Sell	1,245,504 -1	-0%	-$6	1.79%	11
2023 Q4	$7.26M	Hold	1,245,505	–	–	0.94%	11
2023 Q3	$3.19M	Hold	1,245,505	–	–	0.39%	12
2023 Q2	$3.11M	Hold	1,245,505	–	–	0.28%	12
2023 Q1	$2.62M	Hold	1,245,505	–	–	0.24%	12
2022 Q4	$1.93M	Hold	1,245,505	–	–	0.18%	14
2022 Q3	$3.8M	Hold	1,245,505	–	–	0.27%	13
2022 Q2	$3.92M	Hold	1,245,505	–	–	0.25%	13
2022 Q1	$3.49M	Hold	1,245,505	–	–	0.12%	15
2021 Q4	$5.61M	Buy	+1,245,505	New	+$8.99M	0.14%	13

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Deer Management Company's TCRX Position: Q2 2026 in Review

Deer Management Company held its TScan Therapeutics (TCRX) position steady in Q2 2026 at 1,245,504 shares worth $1.22M. The position accounts for 0.15% of the portfolio, ranked #9.

Deer Management Company first reported a position in TCRX in Q4 2021 and has held it in 19 quarters since. The position peaked at $9.89M in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

Deer Management Company held 1,245,504 shares of TScan Therapeutics worth $1.22M as of Q2 2026.
Deer Management Company left its TScan Therapeutics share count unchanged in Q2 2026.
TScan Therapeutics made up 0.15% of Deer Management Company's portfolio in Q2 2026, its #9 holding.
Deer Management Company first reported a position in TScan Therapeutics in Q4 2021 and has held it in 19 quarters since.
Deer Management Company's TScan Therapeutics position peaked at $9.89M in Q1 2024.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Deer Management Company's 13F filing for Q2 2026, filed 14 Aug 2026.